Deslorelin vs Ghrelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Deslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profileGhrelin
Endogenous 28-amino acid peptide secreted primarily by the stomach that functions as both the primary hunger signal and a potent growth hormone secretagogue. The n-octanoyl modification at Ser-3 (acylated form) is required for GHS-R1a receptor binding and GH-stimulating activity. Understanding ghrelin explains the mechanism behind the entire GHRP class of research peptides.
Full profile| Deslorelin | Ghrelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH | GHRL, growth hormone-releasing peptide endogenous, ghrelinergic peptide, acyl ghrelin |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset | 0.5mcg/kg–2mcg/kg mcg/kg, IV or SC bolus; endogenous levels peak pre-meal |
| Administration | Subcutaneous implant (veterinary), Subcutaneous injection | Intravenous (research), Subcutaneous injection |
| Key side effects | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability | Appetite stimulation, Transient hyperglycemia, Water retention, GH pulse stimulation |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Deslorelin is research-stage, while Ghrelin is investigational (in trials).
- Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; Ghrelin — Intravenous (research), Subcutaneous injection.
- Dosing units differ: Deslorelin is dosed in mcg, Ghrelin in mcg/kg — they operate at different scales.
- Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; Ghrelin is IV or SC bolus; endogenous levels peak pre-meal.
How each works
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
Ghrelin
Ghrelin was discovered in 1999 as the endogenous ligand for the GHS-R1a receptor. Its acylated form activates GH release from the pituitary, stimulates appetite via NPY/AgRP hypothalamic neurons, and modulates energy homeostasis and fat storage. The des-acyl form (majority of circulating ghrelin) lacks GHS-R1a activity but has independent cardiovascular and cellular effects.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.